Table 2. Stratified analysis on the association between three-mRNA signature and OS of platinum-sensitive ovarian cancer patients in validating group.
| Variables | Total number | High risk score | Low risk score | HR (95%CI) | P value | |||
|---|---|---|---|---|---|---|---|---|
| Case number | MST (month) |
Case number | MST (month) |
|||||
| Overall | 161 | 81 | 49.7 | 80 | 67.2 | 2.08 (1.35-3.22) | 0.001 | |
| Age (years) | ||||||||
| < 60 | 90 | 46 | 49.7 | 44 | 63.8 | 1.59 (0.90-2.82) | 0.112 | |
| ≥ 60 | 71 | 35 | 43.8 | 36 | 85.9 | 2.39 (1.21-4.70) | 0.006 | |
| Residual Disease | ||||||||
| Macrospcopic disease ≤1cm | 108 | 51 | 48.6 | 57 | 63.8 | 1.81 (1.08-3.34) | 0.021 | |
| Macrospcopic disease >1cm | 39 | 21 | 57.2 | 18 | 85.9 | 2.65 (1.12-6.29) | 0.024 | |
| Pathological grade | ||||||||
| 2 | 25 | 16 | 60.7 | 9 | 85.9 | 2.23 (0.69-7.25) | 0.262 | |
| 3 | 133 | 64 | 48.8 | 69 | 66.5 | 2.06 (1.25-3.37) | 0.002 | |
| FIGO stage, no (%) | ||||||||
| III | 128 | 63 | 51.8 | 65 | 63.8 | 1.65 (1.01-2.72) | 0.043 | |
| IV | 24 | 12 | 45.6 | 12 | 89.1 | 3.87 (1.46-10.3) | 0.004 | |